



Daresbury Proteins

Product description

Page | 1

Name: Recombinant Human Fibroblast Growth Factor Receptor 3, FGFR3b

Synonyms: Fibroblast Growth Factor Receptor 3 (FGFR3)

Species: Human

Source: HEK293

Amino Acids: 23-377

Tag: 10xHis at the C terminus.

Predicted Molecular Weight: 41.2 kDa

Protein ID: P22607-2

Sequence:

ESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELSCPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSG
AYSCRQLTQRVLCHFVSRVTDAPSSGDDDEDGEDEAEDTGVDTGAPYWTRPERMDKLLAVPAANTVRFRCPAAGNPTPSISW
LKNGREFRGEHRIGGIKLRHQWVSLVMSVVPVSDRGNYTCVVENKFGSIRQTYTLDVLESPHRPILQAGLPANQTAVLGSDV
EFHCKVYSDAQPHIQWLKHVEVNGSKVGPDGTYPVTVLKSWISESVEADVRLRLANVSELDGGEYLCRATNFIGVAEKAFWLS
VHGPRAAEELVEADEAGSVYAGGSGHHHHHHHHHHH

Product specifications


Estimated Molecular Weight, SDS-PAGE: ≈55 kDa

Grade & Purity: >95% as estimated by SDS-PAGE stained with Instant Blue Stain (Expedeon).

Daresbury Proteins Ltd. A company registered in England, UK. Company number 10835544.

Address: Daresbury Labs, Keckwick Lane, Warrington WA4 4AD, United Kingdom.

Web address: www.daresburyproteins.co.uk Tel: +44 7398 623734 Email: myprotein@daresburyproteins.co.uk



Endotoxins: Less than 0.1 ng/ μ g (1 IEU/ μ g), as measured by LAL method.

Formulation: PBS 20% Glycerol

Shipping

Product is shipped either on dry or wet ice. Upon receipt, store at -20°C to -70°C.

Product application and Storage

Storage: The protein should be stored at -20°C to -70°C preferably in small aliquots to avoid repeated freeze-thaw cycles.

Stability: At least 12 months at -20°C to -70°C and at least 1 month at 2°C to 8°C.

Application Note: For research purposes only. Not for use in humans.

Daresbury Proteins Ltd. A company registered in England, UK. Company number 10835544.

Address: Daresbury Labs, Keckwick Lane, Warrington WA4 4AD, United Kingdom.

Web address: www.daresburyproteins.co.uk Tel: +44 7398 623734 Email: myprotein@daresburyproteins.co.uk

Background Information

It is a single-pass transmembrane protein composed of three extracellular Ig-like domains, a transmembrane region, and a tyrosine kinase domain (1, 2). Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis (3, 4, 5, 6). Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signalling cascades (6). Activation of PLCG1 leads to the production of the cellular signalling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signalling pathway, as well as of the AKT1 signalling pathway (7, 8, 9). Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signalling (10, 11). Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signalling.

FGFR3b is an alternatively spliced isoform representing epithelial variant of FGFR3.

References:

1. Jaye et al. (1992) *Biochim. Biophys. Acta*, 185-199
2. Johnson and Williams. (1993) *Adv. Cancer Res.*, 1-41
3. Terada et al. (2001) *Mol. Cell Biol. Res. Commun.*, 365-373
4. Ornitz et al. (1996) *J. Biol. Chem.*, 15292-15297
5. Agazie et al. (2003) *Oncogene*, 6909-6918
6. Zhang et al. (2006) *J. Biol. Chem.*, 15694-15700
7. Ben-Zvi et al. (2006) *J. Cell Sci.*, 380-387
8. Harada et al. (2007) *Bone*, 273-281
9. Citores et al. (2007) *J. Cell. Physiol.*, 148-156
10. Krejci et al. (2008) *PLoS ONE*, E3961
11. Salazar et al. (2009) *Hum. Mol. Genet.*, 1951-1961